Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.

Fifteen widely used medications- including two super-popular weight loss drugs – are part of Medicare’s next round of price negotiations, the federal government announced. The Department of Health and Human Services through the Centers for Medicare and Medicaid Services will negotiate with manufacturers directly over the cost of the drugs covered under Medicare Part D,